Judy S. Crabtree, Ph.D., SMB(ASCP)CM

Professor of Genetics

Scientific and Education Director, Precision Medicine Program

Technical Supervisor, Precision Medicine Laboratory

533 Bolivar Street, CSRB 623A
New Orleans, LA 70112
Phone: 504-568-2963
Fax: 504-568-8500





1992  B.S. in Chemistry, University of Oklahoma

1994  M.S. in Biochemistry, University of Oklahoma

1997  Ph.D. in Biochemistry, University of Oklahoma (Advisor: Dr. Bruce A. Roe)

1997-2001 Postdoctoral Fellow, National Human Genome Research Institute, National Institutes of Health (Advisor: Dr. Francis S. Collins)

Selected Publications


J. Yao, E. Bergsland, R. Aggarwal, A. Aparicio, H. Beltran, J.S. Crabtree, C. Hann, T. Ibrahim, L. Byers, H. Sasano, J. Umejiego, and M. Pavel. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940-951 (2022). PMID 35983951.

J.S. Crabtree “Epigenetic Regulation in gastroenteropancreatic neuroendocrine tumors” in special issue on Epigenetics of Rare Cancers, Frontiers in Oncology – Cancer Genetics 12:901435 (2022). PMID: 35747820.

J. Schwartzenburg, R.Reed, H. Koul, A.H. Zea, J. Shellito, L. Miele, J.S. Crabtree, and S. Desai. ISGylation is increased in the peripheral blood mononuclear cells derived from symptomatic COVID19 patients. Experimental Biology and Medicine (Maywood) 247(10):842-847 (2022). PMID: 35130743.

S. Majumder*, J.S. Crabtree*, T.E. Golde, L. Minter, B.A. Osborne, and L. Miele. Targeting Notch in Oncology:  The Path Forward. Nature Reviews in Drug Discovery 20(2):125-144 (2021) PMID: 33293690 *equal contribution

J.S. Crabtree and L. Miele. Breast Cancer Stem Cells. Biomedicines in Special Edition “Stem Cells and Cancer Therapeutics” edited by Lluis Espinosa 6:77 (2018) 

J.S. Crabtree. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Frontiers in Endocrinology, 8:341 (2017). 

E.C. Maggi and J.S. Crabtree. Novel Targets in the Treatment of Neuroendocrine Tumors:  RBP2.  International J. Endocrine Oncology 4(1):31-41 (2017)

J.S. Crabtree and L. Miele. Neuroendocrine tumors: current therapies, Notch signaling and cancer stem cells. J. Cancer Metastasis and Treatment 2:279-93 (2016).

E. Maggi, J. Trillo-Tinoco, A. Parker-Struckhoff, J. Vijayaraghavan, L. Del Valle and J.S. Crabtree. Retinoblastoma Binding Protein 2 (RBP2) is Frequently Expressed in Neuroendocrine Tumors and Promotes the Neoplastic Phenotype. Oncogenesis 5:e257 (2016). 

J. Vijayaraghavan, E.C. Maggi and J.S. Crabtree. miR-24 Regulates Menin in the Endocrine Pancreas. American Journal of Physiology - Endocrinology and Metabolism 307: E84-E92 (2014). 

A.S. McCampbell, H.A. Harris, J.S. Crabtree, R.C. Winneker, C.L. Walker and R.R. Broaddus.  Loss of inhibitory IRS-1 phosphorylation is an early event in mTOR-dependent growth of endometrial hyperplasia.  Cancer Prevention Research3(3): 290-300 (2010).

J.S. Crabtree*, S.A. Jelinsky*, H.A. Harris, S.E. Choe, M.M. Cotreau, M.L. Kimberland, E. Wilson, K.A. Saraf, W. Liu, A.S. McCampbell, B. Dave, R. Broaddus, E. Brown, W. Kao, J.S. Skotnicki, M. Abou-Gharbia, R.C. Winneker and C.L. Walker. Comparison of human and rat uterine leiomyomata: Identification of a dysregulated mammalian target of rapamycin pathway. Cancer Research 69(15):6171-6178 (2009).

J.S. Crabtree, B.J. Peano, X. Zhang, B.S. Komm, R.C. Winneker and H.A. Harris.  Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.  Molecular and Cellular Endocrinology 287(1-2): 40-46 (2008).

J.S. Crabtree, X. Zhang, B.J. Peano, Z. Zhang, R.C. Winneker, H.A. Harris. Development of a Mouse Model of Mammary Gland versus Uterine Tissue Selectivity Using Estrogen- and Progesterone-Regulated Gene Markers. Journal of Steroid Biochemistry and Molecular Biology 101(1): 11-21 (2006).   

J.S. Crabtree, P.C. Scacheri, J.M. Ward, S.R. McNally, G.P. Swain, J.H. Hager, D. Hanahan, H. Edlund, M.A. Magnuson, L. Garrett-Beal, A.L. Burns, S.C. Chandrasekharappa, S.J. Marx, A.M. Spiegel and F.S. Collins. Of Mice and MEN1: Insulinomas in a conditional mouse knockout. Molecular and Cellular Biology 23(17): 6075-6085 (2003).

 S.K. Libutti, J.S. Crabtree, D. Lorang, A.L. Burns, C. Mazzanti, S. Hewitt, J.M. Ward, M. Emmert-Buck, A. Remaley, M. Miller, E. Turner, H.R. Alexander, A. Arnold, S.J. Marx, F.S. Collins and A.M. Spiegel. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Research 63(22):8022-8028 (2003).

J.S. Crabtree, P.C. Scacheri, J.M. Ward, L. Garrett-Beal, M.R. Emmert-Buck, K.A. Edgemon, D. Lorang, S.K. Libutti, S.C. Chandrasekharappa, S.J. Marx, A.M. Spiegel, and F.S. Collins. A mouse model of multiple endocrine neoplasia, type 1 develops multiple endocrine tumors. Proc. Natl. Acad. Sci, USA 98(3):1118-1123 (2001).

The Genome International Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (See website supplemental information for complete author listing).

I. Dunham, N. Shimizu, B.A. Roe, S. Chissoe, et al.  The DNA Sequence of Human Chromosome 22.  Nature 402(6761):489-495 (1999). (See website for complete author listing).

S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weismann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, S.J. Marx.  Positional cloning of the gene for multiple endocrine neoplasia, type 1.  Science 276(5311):404-407 (1997).